arrow
L

Luana Calabrò

university hospital of ferrara
H指数:40
被引数:6,874

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the “Rebiopsy on Osi” study)

EGFR突变型非小细胞肺癌对一线奥希替尼进展:真实世界中的再活检及二线疗法的影响(“Rebiopsy on Osi”研究)

2026-07-250
OAAI
A prospective study on clinicians' attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020)

一项关于免疫治疗时代下,临床医生对晚期非小细胞肺癌(NSCLC)及体力状态较差患者的态度与生存结局的前瞻性研究:PICASO(GOIRC-04-2020)。

2025-06-010
PRE
DNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy

DNA甲基化状态根据其免疫表型对胸膜间皮瘤细胞进行分类:对精准表观遗传治疗的启示

2025-02-180
OA
Nivolumab plus ipilimumab and ASTX727 or nivolumab plus ipilimumab in PD-1 resistant metastatic melanoma: Primary analysis of the randomized phase II NIBIT-ML1 study

纳武利尤单抗联合伊匹木单抗和ASTX727或纳武利尤单抗联合伊匹木单抗治疗PD-1耐药性转移性黑色素瘤:随机II期NIBIT-ML1研究的初步分析

2024-09-010
PRE
Methylation subtypes correlate with tumor immune contextures and outcome to ICI therapy of pleural mesothelioma (PM) patients: The NIBIT EPI-MESO study

甲基化亚型与胸膜间皮瘤(PM)患者肿瘤免疫微环境和ICI疗法结局的相关性:NIBIT EPI-MESO研究

2024-09-010
PRE
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas
2024-09-012
OAAI
Efficacy and Safety of Chemotherapy after Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

晚期非小细胞肺癌患者免疫治疗后化疗的疗效和安全性

2024-06-212
OAAI
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial (vol 199, 113531, 2024)
2024-05-010
PRE
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial
2024-03-017
OA
Stability Program in Dendritic Cell Vaccines: A Real-World Experience in the Immuno-Gene Therapy Factory of Romagna Cancer Center
2022-06-235
OAAI